FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction With FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Sponsor: Blood and Marrow Transplant Group of Georgia
Listed as NCT01328873, this NA trial focuses on Pulmonary Infiltrate New and remains completed. Sponsored by Blood and Marrow Transplant Group of Georgia, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Aug 2017 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Blood and Marrow Transplant Group of Georgia
- Northside Hospital, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .